Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

Number 5: Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening ...

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, ...

Australia’s growing reliance on high-cost biologics for inflammatory skin diseases has placed significant pressure on its ...

Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to ...

Number 5: The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key challenges, including a lack of data in CD and opportunities to improve ...

Alvotech/Teva and Biocon Biologics advanced US biosimilar access with FDA interchangeability for ustekinumab biosimilars, Selarsdi and Yesafili, plus broad 2025 formulary coverage for Biocon’s ...

Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...

Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...